This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Coxon, A. Articles by Kaye, F. J. Search for Related Content PubMed PubMed Citation Articles by Coxon, A. Articles by Kaye, F. J.

Mect1-Maml2 Fusion Oncogene Linked to the Aberrant Activation of Cyclic AMP/CREB Regulated Genes

Genetics Branch and Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute and the National Naval Medical Center, Bethesda, Maryland

Requests for reprints: Frederic J. Kaye, National Naval Medical Center, Building 8, Room 5101, Bethesda, MD 20889. Phone: 301-435-5375; Fax: 301-402-2414; E-mail: fkaye{at}helix.nih.gov.

Malignant salivary gland tumors can arise from a t(11;19) translocation that fuses 42 residues from Mect1/Torc1, a cyclic AMP (cAMP)/cAMP-responsive element binding protein (CREB)–dependent transcriptional coactivator, with 982 residues from Maml2, a NOTCH receptor coactivator. To determine if the Mect1-Maml2 fusion oncogene mediates tumorigenicity by disrupting cAMP/CREB signaling, we have generated in-frame deletions within the CREB-binding domain of Mect1/Torc1 for testing transformation activity and have also developed a doxycycline-regulated Mect1-Maml2 mammalian expression vector for global gene expression profiling. We observed that small deletions within the CREB-binding domain completely abolished transforming activity in RK3E epithelial cells. Further, we have shown that the ectopic induction of Mect1-Maml2 in HeLa cells strongly activated the expression of a group of known cAMP/CREB-regulated genes. In addition, we detected candidate cAMP-responsive element sites within 100 nucleotides of the transcriptional start sites of other genes activated by Mect1-Maml2 expression. In contrast, we did not observe alterations of known Notch-regulated target genes in these expression array profile experiments. We validated the results by reverse transcription-PCR in transfected HeLa, RK3E, and H2009 lung tumor cells and in mucoepidermoid cancer cells that endogenously express the fusion oncopeptide. Whereas overexpression of components of the cAMP pathway has been associated with a subset of human carcinomas, these data provide a direct genetic link between deregulation of cAMP/CREB pathways and epithelial tumorigenesis and suggest future therapeutic strategies for this group of salivary gland tumors.

This article has been cited by other articles:

				Y.-T. Siu, Y.-P. Ching, and D.-Y. Jin Activation of TORC1 Transcriptional Coactivator through MEKK1-induced Phosphorylation Mol. Biol. Cell, November 1, 2008; 19(11): 4750 - 4761. [Abstract] [Full Text] [PDF]

				W.-O. Lui, L. Zeng, V. Rehrmann, S. Deshpande, M. Tretiakova, E. L. Kaplan, I. Leibiger, B. Leibiger, U. Enberg, A. Hoog, et al. CREB3L2-PPAR{gamma} Fusion Mutation Identifies a Thyroid Signaling Pathway Regulated by Intramembrane Proteolysis Cancer Res., September 1, 2008; 68(17): 7156 - 7164. [Abstract] [Full Text] [PDF]

				M. Winnes, F. Enlund, J. Mark, G. Stenman, I. Fonseca, C. Martins, and F. J. Kaye The MECT1-MAML2 Gene Fusion and Benign Warthin's Tumor: Is the MECT1-MAML2 Gene Fusion Specific to Mucuepidermoid Carcinoma? J. Mol. Diagn., July 1, 2006; 8(3): 394 - 396. [Full Text] [PDF]

				F. J. Kaye Emerging Biology of Malignant Salivary Gland Tumors Offers New Insights into the Classification and Treatment of Mucoepidermoid Cancer. Clin. Cancer Res., July 1, 2006; 12(13): 3878 - 3881. [Full Text] [PDF]

				M. Okabe, S. Miyabe, H. Nagatsuka, A. Terada, N. Hanai, M. Yokoi, K. Shimozato, T. Eimoto, S. Nakamura, N. Nagai, et al. MECT1-MAML2 Fusion Transcript Defines a Favorable Subset of Mucoepidermoid Carcinoma. Clin. Cancer Res., July 1, 2006; 12(13): 3902 - 3907. [Abstract] [Full Text] [PDF]